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Abstract
Background: A great deal of the public’s money has been spent on cancer research but demonstrable benefits to
patients have not been proportionate. We are a group of scientists and physicians who several decades ago were
confronted with bimodal relapse patterns among early stage breast cancer patients who were treated by
mastectomy. Since the bimodal pattern was not explainable with the then well-accepted continuous growth
model, we proposed that metastatic disease was mostly inactive before surgery but was driven into growth
somehow by surgery. Most relapses in breast cancer would fall into the surgery-induced growth category thus it
was highly important to understand the ramifications of this process and how it may be curtailed. With this
hypothesis, we have been able to explain a wide variety of clinical observations including why mammography is
less effective for women age 40–49 than it is for women age 50–59, why adjuvant chemotherapy is most effective
for premenopausal women with positive lymph nodes, and why there is a racial disparity in outcome.
Methods: We have been diligently looking for new clinical or laboratory information that could provide a
connection or correlation between the bimodal relapse pattern and some clinical factor or interventional action
and perhaps lead us towards methods to prevent surgery-initiated tumor activity.
Results: A recent development occurred when a retrospective study appeared in an anesthesiology journal that
suggested the perioperative NSAID analgesic ketorolac seems to reduce early relapses following mastectomy.
Collaborating with these anesthesiologists to understand this effect, we independently re-examined and updated
their data and, in search of a mechanism, focused in on the transient systemic inflammation that follows surgery to
remove a primary tumor. We have arrived at several possible explanations ranging from mechanical to biological
that suggest the relapses avoided in the early years do not show up later.
Conclusions: We present the possibility that a nontoxic and low cost intervention could prevent early relapses. It
may be that preventing systemic inflammation post surgery will prevent early relapses. This could be controlled by
the surgical anesthesiologist’s choice of analgesic drugs. This development needs to be confirmed in a randomized
controlled clinical trial and we have identified triple negative breast cancer as the ideal subset with which to test
this. If successful, this would be relatively easy to implement in developing as well as developed countries and
would be an important translational result.
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Background
We are an eclectic group of scientists and physicians
who have been working for almost two decades on an
unusual research project dealing with breast cancer. In
this project we are not conducting laboratory research
nor are we treating patients with experimental therapies.
We are deconstructing clinical data using powerful nu-
merical and computational tools and trying to under-
stand what was the actual tumor growth activity that
could have produced these data. We are then extrapolat-
ing these findings to predict new methods of therapy
that take advantage of the extraordinary temporal pat-
terns of tumor growth and spread. It has been brought
to our attention that this is leading toward translational
research which according to Wang and Marincola repre-
sents the need to find cost-effective solutions to the
treatment of chronic diseases which represents 2/3 of
health care spending in most countries [1]. Translational
research is a way of thinking about and conducting
scientific research to make the results of research applic-
able to the population under study. In the field of medi-
cine, for example, it is used to translate the findings in
basic research more quickly and efficiently into medical
practice and, thus, meaningful health outcomes, whether
those are physical, mental, or social. Translational is a
label for a research approach that seeks to move “from
bench to bedside” or from laboratory experiments
through clinical trials to actual point-of-care patient
applications (from Wikipedia). We are translators start-
ing from clinical findings, looking at biology and then
coming back to clinics. Our manner of investigation is
significantly closer to the actual disease course than re-
search that starts from basic research, at least in our
opinion.
It is ironic that, as described later, we have also been
accused of publishing research that was anti-translational
in breast cancer.
Our project started off in the 1990s when two reports
were published from different countries describing bi-
modal relapse patterns among women treated for early
stage breast cancer [2,3]. That is, after breast cancer is
discovered and surgically removed, the real danger is
that it will come back in other organs such as lung, liver,
bones and brain where treatment is much less success-
ful. That is the common path leading to breast cancer
death. In these new data, there was an early wave of
relapses in the first four years and then a period when
very few such events happened. This was then followed
by a second much broader wave of relapses that peaked
at about 6 years and extended to 10–15 or more years.
Milan data that we have analyzed in detail are shown in
Figures 1 and 2. A difference between pre- and post-
menopausal relapse hazard may be seen. Bimodal pat-
terns have now been identified in 20 independent breast
cancer databases from US, Europe and Asia [4]. This is
apparently not restricted to breast cancer as we have
noted similar recurrence dynamics among patients who
are resected for primary control of prostate, lung, and
pancreatic cancers, as well as osteosarcoma and melan-
oma [5-11].
The most extraordinary part is that the early wave
occurs at a constant period after surgery, irrespective of
the stage of the disease, which cannot be explained by
the conventional ideas of spread of solid tumors. The
magnitude, but not the timing of this wave is related to
clinical factors. These recurrence dynamics were not
explainable using the then well-accepted continuous
growth description for primary and metastatic tumors
nor did it agree with the analysis of local relapse occur-
rences [12]. Conventional models would suggest that re-
lapse should occur earlier for advanced stages and vice
versa.
We thereby reasoned that something was clearly
wrong with the continuous growth description. This was
not just an academic issue. Tumor growth was com-
monly considered to be described by the damped expo-
nential Gompertz equation [13-16]. That is, rapid
exponential growth when it is small but gradually slow-
ing as the tumor enlarges. Since chemotherapy is most
effective when tumors are growing rapidly, the way to
use these drugs is to assume metastatic cancer is present
just after surgery but too small to be detected yet. If it is
there at all, it is growing at the most rapid rate possible
and thus most responsive to cytotoxic drugs that inter-
fere with cellular proliferation and/or division. The strat-
egy then is to treat intensely as soon as possible up to
the limits of tolerability and then stop and hope that any
microscopic tumors were eradicated. The conventional
adjuvant treatment model is not much more compli-
cated than that [16]. It works some of the time but not
nearly often enough to satisfy either patients or their
physicians.
Our project was initially supported by a small grant to
make a computer simulation of the Milan data to create
an expert system with which we could develop prognos-
tic tools and hopefully design new therapies. Based on
computer simulation, we eventually proposed that tumor
growth was far from continuous but rather intermittent
and dynamically non-random in some important ways.
We found that most relapses in breast cancer are the
result of sudden metastatic growth that starts at or
about the time of primary tumor excision. That is, some-
thing happens around the time of surgery that kicks off
growth of tumors resulting in relapses within four years.
This is all described in our several reviews that are
available freely on-line and does not need to be exten-
sively discussed here [4,17,18]. To summarize, we pro-
posed that metastatic tumor growth is mostly inactive
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before primary surgery but much happens afterwards.
The surgery-synchronized early relapses include new
growth from single cells and surgery-induced angiogen-
esis from existing dormant avascular micrometastases.
The late relapses (> 4 years) are not synchronized to sur-
gery and occur gradually for the remainder of the lives
of patients at risk.
Between 50% and 80% of relapses result from surgery
initiated growth. This predominant proportion increases
with the size of the primary tumor. For tumors < 1 cm
in diameter, 50% of those tumors destined to recur, did
so very early. For larger tumors the effect increased to
80%. Surgery-induced angiogenesis of dormant avascular
micrometastases occurred in 20% of premenopausal
women with positive lymph nodes. This mode of relapse
also occurred among other categories of patients. It was
2:1 more common for premenopausal compared to post-














Figure 1 Hazard of relapse for premenopausal patients treated at Istituto Nazionale Tumori in Milan, Italy. Hazard is the number of
events that occur in a time interval divided by the number of patients who enter that time as event free. Patients were treated by mastectomy
well before the routine use of adjuvant therapy. The time interval in all hazard figures used here is 3 months. Average and standard deviations














Figure 2 Hazard of relapse for postmenopausal patients treated at Istituto Nazionale Tumori in Milan, Italy. Definitions are the same as
indicated in Figure 1 but the patient population is postmenopausal.
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among node positive contrasted to node negative ones.
In premenopausal patients, timing of surgery within the
menstrual cycle impacts outcome according to some
investigations [19]. While this concept still needs con-
firmation from well-designed randomized clinical trials,
it points out the importance of the host/tumor environ-
ment at the time of surgery [20,21].
There are indications that this general effect was
recognized long ago. Remarkably, surgeons 2000 years
ago were able to remove breast tumors and many
patients survived the surgery. Aulus Cornelius Celsus
(30BC – 38 AD) wrote: “First there is the cacoethes,
then carcinoma without ulceration, then the fungating
ulcer. None of these can be removed but the cacoethes:
the rest are irritated by every method of cure. The more
violent the operations the more angry they grow. Some
use caustics, some burning iron, others remove the
growth with the scalpel. After excision, even though a
cicatrix is formed, it recurs, bringing with it the cause of
death, whereas at the same time, most people, by using
no violent methods to attempt the extirpation of the dis-
ease but only applying mild medications to soothe it,
protract their lives, notwithstanding the disorder, to an
extreme old age.” This is of course relative to the life
expectancy in those times. Galen (131 – 203 AD) wrote:
“We have often cured this disease in the early stages, but
after it has grown to a noticeable size no one has cured
it with surgery” [22]. So we are certainly not the first to
notice that removing breast tumors can sometimes ac-
celerate disease and that this increases with tumor size.
The most important findings of our early work are
that something happens at or about the time of surgery
to accelerate or induce metastatic activity that results in
early relapses. These early relapses comprise over half of
all relapses. Surgery-induced angiogenesis of dormant
avascular micrometastases and surgery-induced activity
of single malignant cells are implicated. Late relapses are
apparently not synchronized to the time of surgery.
How does this experience fit in terms of translational
cancer research? Children’s Hospital and Harvard Med-
ical School considered it a significant scientific devel-
opment and with Judah Folkman’s approval issued a
press release when one of our papers was published in
International Journal of Surgery [23].
In that paper, we reported that we could explain the
controversial results of early detection of breast cancer
for women age 40–49. The probability of surviving
breast cancer decreases dramatically as the primary
tumor size and the number of axillary lymph nodes posi-
tive for cancer increases. Since a patient diagnosed with
large tumor and multiple lymph nodes logically could
have been diagnosed with smaller tumor and fewer posi-
tive nodes at some time in the past, it made perfect
sense that detection at an earlier time would have
resulted in improved outcome. The amount of benefit
was not known so, beginning in the 1960s, clinical trials
of early detection were initiated in US, UK and Sweden.
As data were emerging years later, it was clear that for
women age 50–59 there was a strong and early appear-
ing 15 to 20% mortality advantage to screening
mammography.
When data for women age 40–49 were examined,
however, there was a clear and wholly unexpected mor-
tality excess in the intervention arms. This excess mor-
tality lasted for six to eight years in the various
randomized controlled trials, but was clearly present.
After this six to eight year span, some benefit showed
up. This caused high anxiety and scientific and emo-
tional consternation. At a NIH consensus conference
called on the subject, an expert panel concluded that
early detection should begin at age 50 years. After much
argument, a second expert panel was then formed that
concluded mammography should begin at age 40. Argu-
ments ensued that are still continuing years later.
We stepped into this ruckus by publishing that the
Milan data suggest surgery-induced angiogenesis for
premenopausal node positive patients would produce 1
early relapse per 10,000 persons age 40–49 who were
screened for early detection. The deaths from this effect
would appear 2–3 years after the start of the trial. This
was very close to what was reported in trials and over-
views. Our findings agreed with trial data that early de-
tection worked better for postmenopausal women than
it did for premenopausal women and may in fact harm
some young women.
This got much attention including a 1200 word write-
up in the Wall Street Journal by Pulitzer Prize winning
reporter Amy Marcus [24]. Our findings at this juncture
were good science but not what some people wanted to
hear. Our findings were, in some peoples’ opinions, a
step backward in their efforts to get women screened
with mammography starting at age 40 (or even younger).
In their opinions, this was opposite to translational
research. It showed early detection - the highly accepted
way to improve outcome in breast cancer – could in
some cases paradoxically result in earlier death than if
they were not screened. There were many angry people
and they were angry at us and any others who openly
discussed the paradox [25]. Mammography and the
resulting biopsies, histopathologic, biochemical and gen-
etic analyses of tissue samples and extensive additional
imaging resulting represent very big and profitable busi-
ness for medical practitioners and various connected
medical-industrial institutions. Of course other advo-
cates of mammography starting at age 40 were moti-
vated by the most altruistic of reasons fully believing
early detection saves lives and wanting this to be univer-
sally practiced.
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We attempted to steer clear of producing clinical un-
certainty [26]. "We say this is indirect evidence; we think
this is a key to understanding the biology of breast can-
cer," Retsky told WebMD. "We certainly do not suggest
any changes in clinical practice based on this. We hope
this will entice clinical and experimental people to test
these hypotheses."
Without going into too many details, we nonetheless
got dragged into the mammography wars and it became
quite an unpleasant situation. “Don’t believe any of this”
came as a quoted comment from the director of screen-
ing for American Cancer Society [26]. In addition, there
were emails from a prominent mammography propon-
ent asking Dr. Folkman, who was coauthor of one of our
papers, to remove his name as coauthor so as to reduce
credibility of our papers suggesting surgery can some-
times accelerate metastatic tumor growth. There was an
angry and insulting letter to the editor of a journal that
published one of our papers asking why the paper in
question did not get picked up by peer reviewers as ob-
viously wrong [27]. The Director of the National Cancer
Institute declared that the mammography controversy is
over [28]. The US Senate voted 98–0 that mammog-
raphy should be routine for women age 40–49 [29].
Meanwhile, we were publishing papers and submitting
grant proposals to support our research. As evidence of
the soundness of our findings, we naively reported that
based on clinical data we could quantitatively explain
the mammography paradox. But this tactic apparently
backfired. Our proposals did not survive triage. As an
apparent result, there was an unpleasant span of years
during which we had no financial support. This was a
low spot in our research. The simulation research that
was conducted in the US was halted (but the clinical
research continued in Italy) and we continued to publish
papers. We report this since researchers intending to
conduct translational research should be aware that their
findings might intentionally or unintentionally trespass
on sensitive terrain with unfavorable results.
There was one very important favorable outcome from
the publicity on our papers that needs to be mentioned.
Two of the letters sent to Editor of International Journal
of Surgery in response to our paper led us into a new
research topic. One was from an African American at-
torney who asked if what we reported could explain why
African Americans commonly say that “cancer spreads
when the air hits it” or words to that effect [30]. The
other letter was from Dr. Isaac Gukas who is a breast
surgeon in UK but spent 15 years practicing oncology in
his native Nigeria [31]. Dr. Gukas noted that in Nigeria
it was typical for women to present in their early 40s
with breast cancer but often decline treatment by a
physician, instead seeing a traditional practitioner who
would prescribe herbal remedies. Their fear was that
surgery would “provoke the cancer”. When eventually
these persons went to a physician it was often with
locally advanced disease. Outcome after intervention
was poor.
It did not take us long to discover that African Americans
present with breast cancer at average age 46 years while
European Americans present at average age 57 years.
Thus African American breast cancer is mostly preme-
nopausal while European American breast cancer is
mostly postmenopausal. This train of thought led us to
write a number of papers with Dr. Gukas as co-author
proposing an explanation of the racial disparity in breast
cancer outcome based on this now expanding theory
[32-34]. It is quite possible that if most trials of mam-
mography were conducted in Nigeria instead of Sweden,
there would have been little if any benefit shown and
mammography would not be a common practice today.
Getting back to breast cancer research, we are now
funded again and vigilantly searching for new data that
will teach us more about surgery-induced tumor activity
and that may ultimately lead to improved post-resection
breast cancer outcomes.
Results
There has been an important recent development. A
paper was published in an anesthesiology journal in June
2010 that reported on a retrospective study of 327 con-
secutive mastectomy patients treated in one Brussels
hospital and by one surgeon [35]. Normally, anesthesiol-
ogists have a 30-day window of interest. If the patients
are alive and as well as can be expected 30 days after a
surgical intervention, the anesthesiologist considers his
or her job done satisfactorily. In the Brussels report
however the patients were examined for metastatic re-
lapse events for up to 4 years post surgery and grouped
by what analgesic drug was used perioperatively.
Approval of the Ethical Committee of St-Luc Hospital
was provided by the Commission d'Ethique Biomédicale
Hospitalo-Facultaire de l'Université catholique de Louvain
(CEBH) of the Université Catholique de Louvain (Brussels,
Belgium), Chairperson Prof Dr. J.M. Maloteaux. Investi-
gators were unable to obtain consent from the patients
for this retrospective study and the need for written
informed consent from participants was waived, as
accepted by the CEBH.
Patients were treated with mastectomy and conven-
tional adjuvant therapy. Chemotherapy, radiotherapy,
and endocrine therapy were performed according to
international expert consensus protocols (9th and 10th
St-Gallen consensus). Follow-up in that initial report
was average 27.3 months with range 13–44 months.
Patients who received anti-inflammatory drugs were
compared with those who had not and their hazard of
recurrence was analyzed and compared. We now report
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an independent update of those data as of September
2011.
The startling result was that one low cost drug- the
non steroidal anti-inflammatory (NSAID) ketorolac –
was strongly associated with far better four year breast
cancer outcome than any of the other three non-NSAID
analgesics (sufentanil, clonidine, and ketamine). The
early relapses that we have associated with surgery are
all but absent among patients who had been given peri-
operative ketorolac [36]. These data from the Brussels
study are shown as updated September 2011 in Figure 3.
Discussion
Even with the insight of simulations, it is sometimes im-
possible to determine with certainty what happened to
each of the various relapse modes in a particular report.
However in this case, it appears that perisurgical ketoro-
lac may dramatically reduce the initiation of surgery-
induced angiogenesis as well as single cell proliferation
after surgery. If this observation holds up to further
scrutiny, it could mean that the simple use of this safe
and effective anti-inflammatory agent at the time of sur-
gery might eliminate most early relapses.
Published along with the original Forget et al. study, an
outline of a number of possible effects of surgery and
anesthesia on cancer growth was presented by Gottschalk
et al. [37]. These include stress, immunosuppression,
pain, transfusion, inflammation, hypothermia, and a few
others. In view of the extensive literature discussing
connections and correlations between cancer growth
and inflammation, our interest was drawn toward inflam-
mation as possibly a key metastasis producing process.
Balkwill et al. write that if genetic damage is the
“match that lights the fire” of cancer, then inflammation
is the “fuel that feeds the flames” and that inflammation
affects both the survival and proliferation of already
initiated cancer cells [38]. Since Virchow first proposed
in 1863 that tumors could originate from sites of chronic
inflammation, it has been well established that chronic
inflammation both contributes to cancer progression
and predisposes tissue to various types of primary and
metastatic cancer [39].
Based on Pascual et al. data from a colon cancer study,
transient inflammation can also be both local and sys-
temic [40]. They measured the proinflammatory cyto-
kine interleukin-6 (IL-6) in serum prior to surgery and
in peritoneal fluid during surgery to establish baseline
IL-6, and again at 4, 12, 24 and 48 hours and at 4 days
after surgery to determine a temporal trend. They found
levels of IL-6 in serum at approximately 1/300 of the
concentrations seen in peritoneal fluid. Judging by their
data it would seem that levels in serum would gradually
return to baseline in a week or so. While not breast can-
cer surgery we can assume that systemically and transi-
ently something similar occurs in surgery to remove
breast cancer.
The inflammatory response is initiated by tissue dam-
age and can be intensified by mast cells, which release
histamine, which then markedly increases the permeabil-
ity of adjacent capillaries. The severity, timing, and local
character of any particular inflammatory response de-
pend on the cause, location and site of the area affected,
and host’s condition [41]. Inflammatory oncotaxis, a
term used to describe tumor growth at a site of inflam-
mation, is occasionally seen in persons with known or
occult cancer and who have local trauma [42-45]. (Note
in particular the El Saghir et al. case report and the pub-
lished comments [44].) Martins-Green et al. studied an
avian system in which a virus is the carcinogenic agent
[46]. When newly hatched chicks are given injections of
Rous sarcoma virus, a tumor develops only at the site of
injection unless a wound is made a distance away from
the primary tumor where a tumor develops at the site of
wounding. They found that when inflammation was
Months 0 6 12 18 24 30 36 42 48
Patients at risk 316 302 283 266 260 252 223 183 150
Keto group 175 168 162 157 155 151 140 115 99
No-Keto group 141 134 121 109 105 101 83 68 51
Figure 3 Forget et al. data were updated September 2011 and
shown in hazard form. Patient data are presented in the table.
Patients included in this figure were less than 80 years of age, tumor
less than 9 cm diameter and disease free survival greater than
2 months. It can be seen that relapses in months 9–18 accounted
for the major difference between ketorolac and non-ketorolac
patients. Data were provided by Sarah Amar and analyzed by
Romano Demicheli.
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inhibited, tumors were also inhibited; when inflamma-
tion could not be stopped, tumors developed as before.
We have two categories of hypotheses that may ex-
plain Forget et al. data of outcome for patients treated
with ketorolac or not. While there is some overlap, the
first is more or less mechanical and the second is bio-
logical in nature. Figure 4 shows a schematic description
of what we suspect to be at least some of the mechan-
isms governing metastatic relapse from early breast
cancer.
Mechanical explanation for Forget et al. data
It is well established that many cancer patients have cir-
culating cancer cells [47,48]. Camara et al. have been
studying circulating epithelial cells that might or might
not be tumor cells. In 11 patients who were monitored
before surgery and 10 minutes and 30 minutes after sur-
gery, the immediate release of cells during surgery was
analyzed. There was almost no change in cell numbers
during this early time after surgery. However, in another
group of 25 patients, cell numbers increased steeply by
an average of over ten-fold in 85%of patients by the third
day after surgery. There was a wide range from a slight
decrease to 1000 fold increase. The average returned to
nearly pre-surgery levels at the next measurement 7 days
after surgery [49]. Such a delayed increase in what may
be circulating cancer cells after breast cancer surgery
was indicated in data by Daskalakis et al. [50].
Perhaps the transient systemic inflammation accom-
panying surgery and subsequent inflammatory oncotaxis
is part of the metastatic tumor seeding process. It may
be that what we previously called dormant single cells
induced into metastatic growth were at least in some
cases residing not at the site of eventual relapse. Rather,
circulating cancer cells in an inflammatory environment
extravasate, resulting a number of months later in a
metastatic tumor. Circulating cancer cells are well docu-
mented. Surgical induction of inflammation is apparently
universal. Capillary leakage is obviously enhanced by
inflammation. While it depends on specific organs and
physiologic conditions, blood flow in capillaries has
been measured at approximately 0.5 mm/sec which
could make leaky capillary venules a very efficient way
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Figure 4 Symbolic description of proposed mechanical and biological explanations for Forget et al. data. Early relapses are assumed to
be related, at least in part, to the inflammatory process due to primary tumor surgical removal, directly or indirectly eliciting peritumoral
endothelial cell proliferation according to the biological mechanisms. A) Angiogenic factors, like VEGF and bFGF, are directly released or even
produced via IL-6; B) Bone marrow derived CXCR-4 positive cells, acting both on tumor foci and on the inflammatory process, are mobilized by
SDF-1, directly released or even produced via COX-2. Perioperative Ketorolac would restrict both endocrine and cellular pathways, thus impairing
the metastatic process. CTC refers to circulating tumor cells. Also shown is how a mechanical explanation prevents these early relapses. Capillary
leakage from transient systemic inflammation as a result of the surgery in the presence of circulating cancer cells and cells released during
surgery and resulting inflammatory oncotaxis is blocked by directly preventing the inflammation. This prevents single cell activation. In addition,
NSAIDS have antiangiogenic properties thus surgery-induced angiogenesis is prevented.
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reducing their concentration in circulation [51]. It is
thereby logical to expect that an effective peri-surgical
anti-inflammatory strategy may affect surgery-induced
single cell activation and resulting cancer spread.
There are only a few relapses in the ketorolac data
shown in Figure 3 that appear to be surgery-induced
angiogenesis events. This may be attributed to the
reduced usage of opioids for pain management with
ketorolac and also the antiangiogenic properties of
NSAIDs [52,53].
Biological explanation for Forget et al. data
The hypothesis that decreasing the inflammatory re-
sponse to the surgical maneuver could interfere with the
angiogenesis switch of avascular micrometastases is not
outlandish. A few hypotheses can be put forward, in-
cluding, but not limited to, the following. At steady-state
conditions in adult mammals, most endothelial cells are
quiescent and are believed to contribute to organ
homeostasis and tumor dormancy [54]. However, in
response to inflammation the upregulation and release
of factors stimulating endothelial cells to proliferate
could also induce endothelial cells to secrete specific
cytokines that reciprocally support the regeneration of
normal and malignant stem cells.
The metastatic process is believed to be supported by
tumor stem cells, which are able to reproduce the can-
cer progeny. Tumor stem cells, as normal stem cells, re-
quire a supporting “niche”, i.e. a subset of tissue cells
and extracellular substrates defining a specialized
microenvironment that is able to modulate the stem
cell function (quiescence or proliferation). The occur-
rence of a metastatic “vascular niche” where endothelial
cells play a main role and where an angiogenesis
dependent dormancy could result from the cross-talk
between tumor cells and endothelial cells (perhaps by
regulation of the Notch signaling) has been suggested
[55]. If cancer stem cells need to interact with a vascu-
lar niche to express their potential, it is reasonable that
the latter, under an angiogenic spike by the surgical ap-
proach to primary tumor, may appreciably contribute to
dormancy interruption. If so, reducing inflammation
could result in impairment of the dormant foci wake up
process [56].
Tissue lesions induce mobilization of bone marrow
derived cells that are capable of responding to chemo-
attractant signals from various organs, where they
undergo a homing process and where they release sev-
eral chemokines [57]. This phenomenon is prominent
during neovascularization of wounded tissues via direct
or paracrine activity inducing capillary formation. A
common basis of the above-mentioned processes is cell
trafficking. Indeed, while the intravascular dissemination
of normal stem cells is essentially passive, mobilization
from their usual niche and homing in a given tissue is
regulated by specific signals. Hematopoietic stem cells,
for example, express the chemokine receptor CXCR4
and selectively respond to SDF-1α. The SDF-1/CXCR4
axis is a main regulator of the normal cell trafficking
underlying the tissue homeostasis. It is also involved in
tumor cell trafficking as CXCR4 overexpression is
known in more than 20 human tumor types, including
ovarian, prostate, esophageal, melanoma, neuroblastoma,
and renal cell carcinoma [58].
NSAIDs may interfere with SDF1 levels via the path-
way COX-2 - > PGE - > SDF-1, thus resulting in impair-
ment of processes underlying metastasis development. It
cannot be excluded that all the above-mentioned
mechanisms could act together. It has been recently
reported in an animal model, where mice with subcuta-
neous implantation of Lewis Lung Carcinoma were sub-
jected to an operative injury, that surgery induced the
release of cytokines/chemokines and mobilized bone
marrow-derived cells [59]. These mobilized cells were
then recruited into tumor tissue with concomitant en-
hancement of angiogenesis, thereby accelerating tumor
growth. Furthermore, blocking recruitment of bone mar-
row stem cells by disrupting SDF/CXCR signals com-
pletely negated the accelerated tumor growth.
The mechanical and biological explanations may both
be right. We suspect that for a few critical days post sur-
gery, transient systemic inflammation triggers changes of
the steady dormant status in the micrometastatic sites,
where tumor cells together with their tumor associated
cells lodge in metastatic niches or even may allow circu-
lating tumor cells and cells released from surgery to
enter tissue. These procedures result in relapses within
the subsequent four years.
Are the missing early relapses in Forget et al. data
never to happen or are they merely postponed to be-
come late relapses? Whatever their source, cancer cells
in circulation probably have half lives of a few days or
less. Unless injected into more hospitable surroundings
such as tissue, these cells will likely harmlessly die off.
These data and our analysis suggest that at least for
some patients the early relapses apparently avoided in
the Forget et al. data do not show up later.
Perhaps ketorolac administered perioperatively is the
right drug, at the right time, to prevent both surgery-
driven angiogenesis and surgery-driven single cell activa-
tion. Indeed, the early relapses in the Brussels data are
reduced by five-fold for patients treated with NSAID
ketorolac compared to the other analgesics. We consider
triple negative breast cancer, a poor prognosis group, to
be an ideal subgroup with which to conduct a rando-
mized clinical trial of ketorolac vs. a placebo control to
test whether this observational study stands up to more
robust scrutiny [36].
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Conclusions
 Our findings suggest that most relapses occurring
within 4 years may be induced by the effects of
breast cancer surgery.
 Possible mechanisms are surgery-induced
angiogenesis of dormant avascular micrometastases
and transient systemic inflammation which, via the
upregulation and release of factors stimulating
endothelial cells to proliferate and the activation of
the so called “vascular niche” will stimulate tumor
growth or even, in the presence of circulating cancer
cells and cells released as a result of surgery,
produce what has been called inflammatory
oncotaxis.
 We have found that peri-operative anti-
inflammatory agents appear to abrogate the early
hazard of recurrence and we estimate that such
intervention could reduce breast cancer mortality by
25% to 50%.
 High priority should be given to test this hypothesis
in a randomized trial as it is implementable
regardless of state of socio-economic development
because expensive drugs, modern imaging facilities
and advanced pathology services are not particularly
relevant to implementing this simple change.
 Also as noted by Wallace et al. [60], the racial
disparity in breast cancer outcome is due primarily
to deaths within the first few years after diagnosis
providing an additional motivation to test at the
earliest opportunity what we report here.
This needs to be confirmed and if found true would
be an ideal inexpensive and non-toxic solution for a sig-
nificant fraction of the early relapse problem in breast
cancer. Now that sounds like translational research.
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